Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
NCT ID: NCT00425126
Last Updated: 2010-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
76 participants
INTERVENTIONAL
2007-02-28
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intraoperative Fluid Therapy for Deceased Donor Renal Transplantation
NCT02512731
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
NCT05081739
DCreg in Living Donor Liver Transplantation
NCT03164265
The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
NCT00617474
The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients
NCT07275632
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epoetin Alfa
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18
* Deceased donor kidney transplant
Exclusion Criteria
* Receiving Coumadin or Heparin
* Hemoglobin \>=14 g/dl
* Uncontrolled hypertension
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West Penn Allegheny Health System
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard J Marcus, MD
Role: PRINCIPAL_INVESTIGATOR
West Penn Allegheny Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol. 2012 Sep;7(9):1498-506. doi: 10.2215/CJN.01360212. Epub 2012 Jun 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC-4044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.